It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
AZN’s FA Score shows that 2 FA rating(s) are green whileLLY’s FA Score has 2 green FA rating(s), and MRK’s FA Score reflects 2 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
AZN’s TA Score shows that 5 TA indicator(s) are bullish while LLY’s TA Score has 6 bullish TA indicator(s), and MRK’s TA Score reflects 5 bullish TA indicator(s).
AZN (@Pharmaceuticals: Major) experienced а +2.93% price change this week, while LLY (@Pharmaceuticals: Major) price change was +5.31% , and MRK (@Pharmaceuticals: Major) price fluctuated +6.08% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +3.20%. For the same industry, the average monthly price growth was -1.54%, and the average quarterly price growth was -7.79%.
AZN is expected to report earnings on Jul 24, 2025.
LLY is expected to report earnings on Aug 07, 2025.
MRK is expected to report earnings on Jul 29, 2025.
The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
AZN | LLY | MRK | |
Capitalization | 209B | 740B | 332B |
EBITDA | 13.4B | 8.57B | 6.91B |
Gain YTD | 7.698 | 14.775 | -16.109 |
P/E Ratio | 35.30 | 131.13 | 935.64 |
Revenue | 45.8B | 34.1B | 60.1B |
Total Cash | 5.86B | 2.93B | 7.09B |
Total Debt | 28.6B | 25.2B | 35.1B |
AZN | LLY | MRK | ||
---|---|---|---|---|
OUTLOOK RATING 1..100 | 14 | 26 | 54 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 25 Undervalued | 90 Overvalued | 10 Undervalued | |
PROFIT vs RISK RATING 1..100 | 30 | 6 | 70 | |
SMR RATING 1..100 | 50 | 14 | 25 | |
PRICE GROWTH RATING 1..100 | 56 | 46 | 64 | |
P/E GROWTH RATING 1..100 | 67 | 90 | 100 | |
SEASONALITY SCORE 1..100 | 75 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
MRK's Valuation (10) in the Pharmaceuticals Major industry is in the same range as AZN (25) and is significantly better than the same rating for LLY (90). This means that MRK's stock grew similarly to AZN’s and significantly faster than LLY’s over the last 12 months.
LLY's Profit vs Risk Rating (6) in the Pharmaceuticals Major industry is in the same range as AZN (30) and is somewhat better than the same rating for MRK (70). This means that LLY's stock grew similarly to AZN’s and somewhat faster than MRK’s over the last 12 months.
LLY's SMR Rating (14) in the Pharmaceuticals Major industry is in the same range as MRK (25) and is somewhat better than the same rating for AZN (50). This means that LLY's stock grew similarly to MRK’s and somewhat faster than AZN’s over the last 12 months.
LLY's Price Growth Rating (46) in the Pharmaceuticals Major industry is in the same range as AZN (56) and is in the same range as MRK (64). This means that LLY's stock grew similarly to AZN’s and similarly to MRK’s over the last 12 months.
AZN's P/E Growth Rating (67) in the Pharmaceuticals Major industry is in the same range as LLY (90) and is somewhat better than the same rating for MRK (100). This means that AZN's stock grew similarly to LLY’s and somewhat faster than MRK’s over the last 12 months.
AZN | LLY | MRK | |
---|---|---|---|
RSI ODDS (%) | 1 day ago52% | 1 day ago69% | 2 days ago66% |
Stochastic ODDS (%) | 1 day ago48% | 1 day ago47% | 2 days ago62% |
Momentum ODDS (%) | 1 day ago58% | 1 day ago68% | 3 days ago47% |
MACD ODDS (%) | 1 day ago57% | 1 day ago64% | 2 days ago53% |
TrendWeek ODDS (%) | 1 day ago55% | 1 day ago68% | 2 days ago50% |
TrendMonth ODDS (%) | 1 day ago43% | 1 day ago68% | 2 days ago43% |
Advances ODDS (%) | 1 day ago54% | 1 day ago69% | 26 days ago48% |
Declines ODDS (%) | 10 days ago43% | 19 days ago53% | 10 days ago48% |
BollingerBands ODDS (%) | 1 day ago59% | 1 day ago69% | 2 days ago64% |
Aroon ODDS (%) | 1 day ago43% | 1 day ago52% | 2 days ago39% |
A.I.dvisor indicates that over the last year, MRK has been loosely correlated with AZN. These tickers have moved in lockstep 36% of the time. This A.I.-generated data suggests there is some statistical probability that if MRK jumps, then AZN could also see price increases.